Vascular Biology Research Institute, Guangdong Pharmaceutical University, Guangzhou 510006, China.
Department of Thoracic Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, China.
Exp Mol Pathol. 2014 Apr;96(2):195-9. doi: 10.1016/j.yexmp.2013.11.004. Epub 2014 Jan 18.
Non-small cell lung cancer (NSCLC) accounts for approximately 70% of all lung cancer-related deaths worldwide. Prognostic markers are essential for the early detection of lung cancer in patients. In this study, we first identified microRNA146 (miR-146) expression in cancer cell lines using miRNA in situ hybridization (MISH) and confirmed the accuracy of MISH using q-RT-PCR. In addition, two different systems, BCIP/NBT and ELF, were used to detect the signal for a comparative analysis of the specificity of MISH. Compared to the BCIP/NBT system, the ELF detection system was more effective for MISH. Furthermore we detected the expression of miR-146 in NSCLC tissues (43 cases) and normal tissues (32 cases). Based on our results, we can conclude that miR-146 is more highly expressed in cancer tissue than normal tissue (t-test, P<0.05) and that miR-146 can predict the prognosis of NSCLC by MISH. Our findings preliminary demonstrate that MISH can be applied as a molecular diagnostic tool to determine the expression and localization of miRNAs in cancer tissues and that miR-146, determined by MISH, predicts the prognosis of NSCLC patients.
非小细胞肺癌（NSCLC）约占全球所有肺癌相关死亡人数的 70%。预后标志物对于患者肺癌的早期检测至关重要。在这项研究中，我们首先使用 miRNA 原位杂交（MISH）来鉴定癌细胞系中的 microRNA146（miR-146）表达，并使用 q-RT-PCR 来验证 MISH 的准确性。此外，我们使用了两种不同的系统，BCIP/NBT 和 ELF，来检测信号，以进行 MISH 特异性的比较分析。与 BCIP/NBT 系统相比，ELF 检测系统对 MISH 更有效。此外，我们还检测了 NSCLC 组织（43 例）和正常组织（32 例）中 miR-146 的表达。基于我们的结果，我们可以得出结论，miR-146 在癌症组织中的表达高于正常组织（t 检验，P<0.05），并且 MISH 可以预测 NSCLC 的预后。我们的发现初步表明，MISH 可作为一种分子诊断工具，用于确定癌症组织中 miRNAs 的表达和定位，并且通过 MISH 确定的 miR-146 可预测 NSCLC 患者的预后。
